Liminatus Pharma Stock Soars 8.92% on Nasdaq Listing

On June 25, 2025, Liminatus Pharma's stock surged by 8.92% in pre-market trading, marking a significant rise in its share price.

Liminatus Pharma has been one of the top-performing stocks in the market, with its share price experiencing substantial increases over the past month. The company's recent Nasdaq listing has contributed to its stock's impressive performance, as investors have shown strong interest in the company's potential.

In addition to its recent Nasdaq listing, Liminatus Pharma has also regained compliance with Nasdaq's listing requirements, which has further boosted investor confidence in the company. This compliance has led to a surge in the company's stock price, with shares reaching a record high.

Liminatus Pharma has also been actively involved in fundraising efforts, filing to sell 6.9 million shares of common stock. This move is part of the company's broader strategy to raise capital and support its ongoing operations and growth initiatives.